摘要
背景与目的:表皮生长因子受体(epidermal growth factor receptor,EGFR)的异常表达和活化能引起肿瘤细胞化疗耐药的产生,与卵巢癌化疗后复发及预后密切相关。肺耐药蛋白(lung resistance protein,LRP)是一种主要介导铂类等化疗药物耐药的多药耐药蛋白。研究表明,LRP是预测卵巢癌化疗敏感的独立预后因素。本研究探讨EGFR和LRP表达与卵巢癌化疗耐药及预后的关系。方法:采用免疫组化PV-6000二步法,检测76例恶性卵巢肿瘤、9例卵巢交界性肿瘤、17例卵巢良性肿瘤和15例卵巢正常组织中EGFR和LRP的表达,分析EGFR和LRP表达与卵巢癌化疗疗效及患者术后生存时间的关系。结果:卵巢癌组织中EGFR和LRP的阳性率分别为73.68%和71.79%,均显著高于正常卵巢组织和良性肿瘤组织(P<0.01);EGFR高表达于Ⅲ～Ⅳ期、低分化和有腹水的卵巢癌组织中(P<0.05)。EGFR和LRP阳性者近期化疗有效率分别为57.14%和53.70%,低于阴性者(P<0.05);化疗耐药型卵巢癌患者EGFR和LRP阳性率分别为92.86%和85.71%,高于化疗敏感型(P<0.05)。生存分析表明,卵巢癌患者3年生存率为53.00%。EGFR、LRP阳性和近期化疗疗效无效者术后生存时间短(P<0.01)。结论:EGFR和LRP可作为预测卵巢癌化疗耐药及预后的指标。
BACKGROUND ＆ OBJEKTIVE. Abnormal expression and activation of epidermal growth factor receptor （EGFR）, which is closely related to the recurrence and poor prognosis of ovarian cancer, can promote chemotherapy resistance of tumor cells. Lung resistance protein （LRP）, a multidrug resistance protein causing platinum-resistance, is an independent factor in predicting chemotherapy sensitivity to ovarian cancer. This study was to explore the correlations of EGFR and LRP to chemotherapy resistance and prognosis of ovarian cancer. METHODS. Expressions of EGFR and LRP in 76 specimens of ovarian malignant tumor, nine borderline tumor, 17 benign tumor and 15 normal ovary were studied using immunohistochemistry. Patients with ovarian cancer were followed up. Correlations of EGFR and LRP to chemotherapy efficacy and survival time of patients with ovarian cancer after operation were analyzed. RESULTS： The positive rates of EGFR and LRP in malignant specimens （73.68% and 71.79%） were significantly higher than those in normal and benign ones （P〈0.01）. EGFR was highly expressed in ovarian cancer patients at late stage （ Ⅲ-Ⅳ）, with poor differentiation and ascites （P 〈0.05）. The short-term efficacy rates of ovarian cancer were lower in patients with positive expressions of EGFR and LRP （57.14% and 53.70%） than in those with negative expressions （P〈0.05）. The positive rates of EGFR and LRP were significant higher in patients with chemotherapy resistance （92,86% and 85,71%） than in those sensitive to chemotherapy （P〈0.05）. The three-year survival rate of ovarian cancer patients was 53.00%. Patients with positive EGFR and LRP and poor short-term efficacy after chemotherapy had short survival time （P〈0.01）, CONCLUSION： The expression of EGFR and LRP could be used to predict chemotherapy resistance and prognosis of ovarian cancer.
出处
《癌症》
SCIE
CAS
CSCD
北大核心
2008年第12期1331-1336,共6页
Chinese Journal of Cancer
关键词
卵巢肿瘤
EGFR
LRP
化学疗法
耐药
预后
Ovarian neoplasms
Epidermal growth factor receptor
Lung resistance protein
Chemotherapy
Drug resistance
Prognosis
